Open access
Open access
Powered by Google Translator Translator

Allergy & Immunology

M-A | Metabolic adverse events associated with systemic corticosteroid therapy

24 Jan, 2023 | 14:10h | UTC

Metabolic adverse events associated with systemic corticosteroid therapy—a systematic review and meta-analysis – BMJ Open

 


RCT | Lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis

15 Jan, 2023 | 20:07h | UTC

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere) – JAMA Dermatology

 

Commentary on Twitter

 


Phase 1-2 study | Lentiviral gene therapy for artemis-deficient SCID

12 Jan, 2023 | 12:59h | UTC

Lentiviral Gene Therapy for Artemis-Deficient SCID – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Infant gene therapy is a breakthrough for Artemis-SCID patients – University of California – San Francisco

 

Commentary on Twitter

 


SR | Skin care interventions in infants for preventing eczema and food allergy.

12 Dec, 2022 | 12:23h | UTC

Skin care interventions in infants for preventing eczema and food allergy – Cochrane Library

Summary: Skin care interventions for preventing eczema and food allergy – Cochrane Library

 

Commentary on Twitter

 


M-A | Allergen immunotherapy for atopic dermatitis.

9 Dec, 2022 | 13:24h | UTC

Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms – The Journal of Allergy and Clinical Immunology

 


Improving antimicrobial stewardship with penicillin allergy testing: a review of current practices and unmet needs.

27 Nov, 2022 | 22:25h | UTC

Improving antimicrobial stewardship with penicillin allergy testing: a review of current practices and unmet needs – JAC-Antimicrobial Resistance

Related:

Management of Patients with Suspected or Confirmed Antibiotic Allergy. Executive Summary of Guidance from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Allergy and Clinical Immunology (SEAIC), the Spanish Society of Hospital Pharmacy (SEFH) and the Spanish Society of Intensive Medicine and Coronary Care Units (SEMICYUC) – Journal of Investigational Allergology and Clinical Immunology (PDF)

The prevalence of penicillin allergy labeling ranged from 0.9% to 10.2% across practices in a large pediatric cohort, raising questions regarding the validity of those labels and the unnecessary use of second-line antibiotics that may follow.

The prevalence of penicillin allergy labeling ranged from 0.9% to 10.2% across practices in a large pediatric cohort, raising questions regarding the validity of those labels and the unnecessary use of second-line antibiotics that may follow.

M-A: Most patients with allergy to Penicillin can be given Cefazolin

Systematic review: Safety and efficacy of de-labelling penicillin allergy in adults using direct oral challenge

Penicillin allergy labels increase second-line broad-spectrum antibiotic prescribing for pediatric respiratory tract infections

Podcast: A Clinical Pharmacologist’s Perspective on Penicillin Allergy

Study: Development and Validation of a Penicillin Allergy Clinical Decision Rule

Management of a surgical patient with a label of penicillin allergy: narrative review and consensus recommendations – British Journal of Anaesthesia

NICE: Double Check Patients with ‘Penicillin Allergy’ to Avoid Increased MRSA Risk

Cohort Study: Risk of Meticillin Resistant Staphylococcus Aureus and Clostridium Difficile in Patients with a Documented Penicillin Allergy

 


SR | Interventions for the long‐term prevention of hereditary angioedema attacks.

27 Nov, 2022 | 22:12h | UTC

Interventions for the long‐term prevention of hereditary angioedema attacks – Cochrane Library

Summary: Drug treatments for the prevention of attacks of hereditary angioedema – Cochrane Library

 

Commentary on Twitter

 


RCT | Efficacy and safety of Remibrutinib, a novel BTK inhibitor, for chronic spontaneous urticaria.

23 Nov, 2022 | 13:37h | UTC

Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria – The Journal of Allergy and Clinical Immunology

 


M-A | Long-term outcomes of turbinate surgery in patients with allergic rhinitis.

18 Nov, 2022 | 13:09h | UTC

Long-term Outcomes of Turbinate Surgery in Patients With Allergic Rhinitis: A Systematic Review and Meta-analysis  – JAMA Otolaryngology—Head & Neck Surgery (free for a limited period) 

 


SR | Immunostimulants vs. placebo for preventing exacerbations in adults with chronic bronchitis or COPD.

16 Nov, 2022 | 13:34h | UTC

Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease – Cochrane Library

Summary: Is taking an immunostimulant on top of standard medications beneficial for people with chronic obstructive pulmonary disease, chronic bronchitis, or both? – Cochrane Library

 


RCT | Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen.

8 Nov, 2022 | 12:06h | UTC

Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial – Journal of Allergy and Clinical Immunology (link to abstract – $ for full-text)

News Release: Monoclonal antibody improves cat allergen immunotherapy – National Institutes of Health 

Commentaries: Study explores the potential use of anti-thymic stromal lymphopoietin monoclonal antibody as an adjuvant in allergic immunotherapy – News Medical

 


Safety of Upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies.

19 Oct, 2022 | 14:14h | UTC

Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies – Journal of Allergy and Clinical Immunology

Related: Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials – JAMA Dermatology

 


WAO/EAACI guideline for the management of hereditary angioedema.

4 Oct, 2022 | 14:34h | UTC

The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update – Allergy

 


RCT | Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis.

20 Sep, 2022 | 13:20h | UTC

Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet

Commentary: Dupilumab Eases Atopic Dermatitis in Children Younger Than 6 Years – HealthDay

 


Guideline Summary | Management of patients with suspected or confirmed antibiotic allergy.

8 Sep, 2022 | 14:42h | UTC

Management of Patients with Suspected or Confirmed Antibiotic Allergy. Executive Summary of Guidance from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Allergy and Clinical Immunology (SEAIC), the Spanish Society of Hospital Pharmacy (SEFH) and the Spanish Society of Intensive Medicine and Coronary Care Units (SEMICYUC) – Journal of Investigational Allergology and Clinical Immunology (PDF)

Related:

The prevalence of penicillin allergy labeling ranged from 0.9% to 10.2% across practices in a large pediatric cohort, raising questions regarding the validity of those labels and the unnecessary use of second-line antibiotics that may follow.

The prevalence of penicillin allergy labeling ranged from 0.9% to 10.2% across practices in a large pediatric cohort, raising questions regarding the validity of those labels and the unnecessary use of second-line antibiotics that may follow.

M-A: Most patients with allergy to Penicillin can be given Cefazolin

Systematic review: Safety and efficacy of de-labelling penicillin allergy in adults using direct oral challenge

Penicillin allergy labels increase second-line broad-spectrum antibiotic prescribing for pediatric respiratory tract infections

Podcast: A Clinical Pharmacologist’s Perspective on Penicillin Allergy

Study: Development and Validation of a Penicillin Allergy Clinical Decision Rule

Management of a surgical patient with a label of penicillin allergy: narrative review and consensus recommendations – British Journal of Anaesthesia

NICE: Double Check Patients with ‘Penicillin Allergy’ to Avoid Increased MRSA Risk

Cohort Study: Risk of Meticillin Resistant Staphylococcus Aureus and Clostridium Difficile in Patients with a Documented Penicillin Allergy

 


European guideline (EuroGuiDerm) on atopic eczema – Part II | Non-systemic treatments and treatment recommendations for special AE patient populations.

5 Sep, 2022 | 14:32h | UTC

European guideline (EuroGuiDerm) on atopic eczema – part II: non-systemic treatments and treatment recommendations for special AE patient populations – Journal of the European Academy of Dermatology and Venereology

Related: European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy – Journal of the European Academy of Dermatology and Venereology

 


Guideline | Management of kidney transplant patients with HLA antibodies.

31 Aug, 2022 | 11:47h | UTC

European Guideline for the Management of Kidney Transplant Patients With HLA Antibodies: By the European Society for Organ Transplantation Working Group – Transplant International

 


Clinical practice guidelines for the management of atopic dermatitis.

24 Aug, 2022 | 14:13h | UTC

English Version of Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021 – The Journal of Dermatology

 


European guideline on atopic eczema – Part I: systemic therapy.

19 Aug, 2022 | 16:14h | UTC

European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy – Journal of the European Academy of Dermatology and Venereology

 


Review | Plasma exchange in the intensive care unit.

15 Aug, 2022 | 12:19h | UTC

Plasma exchange in the intensive care unit: a narrative review – Intensive Care Medicine

 

Commentary on Twitter

 


M-A | Interventions to reduce infections in patients with hematological malignancies.

15 Aug, 2022 | 11:51h | UTC

Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis – Blood Advances

Commentary: Prophylactic Immunoglobulin, Vaccinations May Reduce Infections in Hematologic Malignancies – AJMC

 


Consensus Statement | Pharmacological management of allergic rhinitis.

11 Aug, 2022 | 12:10h | UTC

Pharmacological Management of Allergic Rhinitis: A Consensus Statement from the Malaysian Society of Allergy and Immunology – Journal of Asthma and Allergy

Related:

Pharmacologic Treatment of Seasonal Allergic Rhinitis: Synopsis of Guidance From the 2017 Joint Task Force on Practice Parameters – Annals of Internal Medicine

Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis – Allergy Asthma & Immunology Research

 


Guideline | Management of immunoglobulin replacement therapy.

5 Aug, 2022 | 14:35h | UTC

British Society for Immunology & United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy – Clinical and Experimental Immunology

 


M-A | Treating eosinophilic esophagitis with budesonide.

27 Jul, 2022 | 12:06h | UTC

A meta-analysis on randomized controlled trials of treating eosinophilic esophagitis with budesonide – Annals of Medicine

 


RCT | Efficacy and safety of Abrocitinib vs. Dupilumab in adults with moderate-to-severe atopic dermatitis.

25 Jul, 2022 | 12:44h | UTC

Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial – The Lancet (link to abstract – $ for full-text)

Related: Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis – New England Journal of Medicine

 


Stay Updated in Your Specialty

No spam, just news.